<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">Colorectal cancers</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) are commonly classified into those with microsatellite instability and those that are microsatellite stable (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>) but chromosomally unstable </plain></SENT>
<SENT sid="1" pm="."><plain>The latter are characterized by poor prognosis and remain largely intractable at the metastatic stage </plain></SENT>
<SENT sid="2" pm="."><plain>Comprehensive mutational analyses have revealed that the mixed lineage kinase 4 (MLK4) protein kinase is frequently mutated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> with approximately 50% of the mutations occurring in KRAS- or BRAF-mutant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>This kinase has not been characterized previously and the relevance of MLK4 <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> has not been established </plain></SENT>
<SENT sid="4" pm="."><plain>We report that MLK4-mutated alleles in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> are constitutively active and increase the transformation and tumorigenic capacity of <z:mp ids='MP_0011356'>RAS</z:mp>-mutated cell lines </plain></SENT>
<SENT sid="5" pm="."><plain>Gene expression silencing or targeted knockout of MLK4 impairs the oncogenic properties of KRAS- and BRAF-mutant <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells both in vitro and in <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In establishing the role of MLK4 in intracellular signaling, we show it directly phosphorylates MEK1 (MAP2K1) and that MEK/ERK (MAPK1) signaling is impaired in MLK4 knockout cells </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that MLK4 inhibitors may be efficacious in KRAS- and BRAF-mutated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> and may provide a new opportunity for targeting such recalcitrant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Res; 73(6); 1912-21. Â©2012 AACR </plain></SENT>
</text></document>